Insights
How long are patients WAITing for new treatments?
2 July 2026
The latest EFPIA Patients W.A.I.T. Indicator 2025 Survey shows that patients across Europe are waiting longer for access to new medicines, with major differences between countries. Here we explain how to interpret the W.A.I.T indicators.
Around the world in HTAs: Abu Dhabi – Advancing HTA and value-based healthcare in the UAE
1 July 2026
Abu Dhabi is taking important steps to strengthen the use of HTA in healthcare decision-making, with the publication of its HTA guidelines in 2025 marking an important milestone.
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
Much of the Most-Favoured-Nation debate asks whether the United States can persuade other countries to pay more for medicines. Germany is the market where that question is hardest to answer and where it matters most.
The cost of inaction on LDL cholesterol
24 June 2026
This Insight is based on the WHA79 panel discussion “Lowering Cholesterol, Increasing Impact: The Case for Earlier Action to Address the CV Epidemic”, co-organised by OHE and MSD, at the World Health Assembly in Geneva, May 2026.
One Europe, one assessment? Unpacking the European Joint Clinical Assessment
28 May 2026
As the first EU Joint Clinical Assessment reports approach, national HTA systems across Europe are already adapting to a new era of coordinated clinical evaluation.
Two numbers, one decision: making climate-health valuation usable across sectors
18 May 2026
An OHE insight, ahead of OHE’s participation in the Health Diplomacy House panel at the 79th World Health Assembly (Geneva, 21 May 2026).
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating a fixed budget, and that it would introduce inequities based on individual productivity or income. We argue that patient and carer time are vital inputs to healthcare, and that ignoring them reduces rather than improves both efficiency and fairness.
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.